{"protocolSection":{"identificationModule":{"nctId":"NCT02175017","orgStudyIdInfo":{"id":"ONO-4538-09"},"organization":{"fullName":"Ono Pharmaceutical Co. Ltd","class":"INDUSTRY"},"briefTitle":"ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer","officialTitle":"ONO-4538 Multicenter, Open-label, Uncontrolled, Phase II Study in Advanced Non-small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2024-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2015-11","type":"ACTUAL"},"completionDateStruct":{"date":"2021-02","type":"ACTUAL"},"studyFirstSubmitDate":"2014-06-18","studyFirstSubmitQcDate":"2014-06-25","studyFirstPostDateStruct":{"date":"2014-06-26","type":"ESTIMATED"},"resultsFirstSubmitDate":"2023-09-01","resultsFirstSubmitQcDate":"2024-10-21","resultsFirstPostDateStruct":{"date":"2024-12-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-10-21","lastUpdatePostDateStruct":{"date":"2024-12-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ono Pharmaceutical Co. Ltd","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The objective of the study is to investigate the efficacy and safety of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based chemotherapeutic regimen."},"conditionsModule":{"conditions":["Advanced Non-small Cell Lung Cancer (NSCLC)"],"keywords":["ONO-4538","Advanced non-small cell lung cancer (NSCLC)","nivolumab"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":104,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"ONO-4538 for squamous non-small-cell lung cancer (NSCLC)","type":"EXPERIMENTAL","description":"In each treatment cycle, patients received an intravenous infusion of nivolumab (ONO-4538) at a dose of 3 mg/kg every 2 weeks for 6 weeks. Changes in dose were not allowed. Radiological assessments (computed tomography/ magnetic resonance imaging) were conducted every 6 weeks. Patients entered subsequent treatment cycles unless they met discontinuation criteria, including disease progression, unacceptable adverse events, and consent withdrawal. Patients who were discontinued for any of these reasons entered the follow-up phase.","interventionNames":["Drug: ONO-4538"]},{"label":"ONO-4538 for non-squamous non-small-cell lung cancer (NSCLC)","type":"EXPERIMENTAL","description":"In each treatment cycle, patients received an intravenous infusion of nivolumab (ONO-4538) at a dose of 3 mg/kg every 2 weeks for 6 weeks. Changes in dose were not allowed. Radiological assessments (computed tomography/ magnetic resonance imaging) were conducted every 6 weeks. Patients entered subsequent treatment cycles unless they met discontinuation criteria, including disease progression, unacceptable adverse events, and consent withdrawal. Patients who were discontinued for any of these reasons entered the follow-up phase.","interventionNames":["Drug: ONO-4538"]}],"interventions":[{"type":"DRUG","name":"ONO-4538","description":"ONO-4538 Study in Patients With Squamous NSCLC","armGroupLabels":["ONO-4538 for squamous non-small-cell lung cancer (NSCLC)"],"otherNames":["nivolumab"]},{"type":"DRUG","name":"ONO-4538","description":"ONO-4538 Study in Patients With Non-Squamous NSCLC","armGroupLabels":["ONO-4538 for non-squamous non-small-cell lung cancer (NSCLC)"],"otherNames":["nivolumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Response Rate (Centrally Assessed)","description":"Response rate (%) = (Number of subjects whose confirmed best overall response was complete response (CR) or partial response (PR) / Total number of FAS)\\*100. 95% Confidence interval (CI) was calculated by Wilson method.","timeFrame":"Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase (up to approximately 10 months).Follow-up phase: 28 days after final dose or for discontinuation occurring 28 or fewer days after final dose."}],"secondaryOutcomes":[{"measure":"Response Rate (Investigator-assessed)","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","timeFrame":"Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase (up to approximately 10 months).Follow-up phase: 28 days after final dose or for discontinuation occurring 28 or fewer days after final dose."},{"measure":"Overall Survival","description":"Overall survival (days) = (the date of death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.","timeFrame":"Follow-up phase: Every 6 months after the first day of treatment of the last subject enrolled in the study, until death or study completion."},{"measure":"Progression Free Survival (Centrally Assessed)","description":"Progression free survival (days) = (the earlier date of the first documented progressive disease (PD) or death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.","timeFrame":"Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or until central PD was confirmed or data cut-off point.Follow-up phase: Until beginning subsequent treatment for non-small cell lung cancer or PD or recurrence."},{"measure":"Duration of Response (Centrally Assessed)","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Duration of response (days) = (the date of the first documented PD or death due to any cause after response was confirmed) - (the date of the first confirmed CR or PR) + 1. Median (95% CI) was calculated by Kaplan-Meier method.","timeFrame":"Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase(up to approximately 10 months).Follow-up phase: Until beginning subsequent treatment for non-small cell lung cancer or PD or recurrence."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female ≥ 20 years of age\n2. Histologically or cytologically confirmed non-small cell lung cancer\n3. Diagnosis of NSCLC in stage IIIB/IV unsuited to radical radiotherapy according to UICC-TNM classification (7th edition) or recurrent NSCLC\n4. Has at least one measurable lesion, as defined by the RECIST guideline (version 1.1)\n\nExclusion Criteria:\n\n1. Current or prior severe hypersensitivity to another antibody product\n2. Multiple primary cancers","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Mitsunobu Tanimoto","affiliation":"Ono Pharmaceutical Co. Ltd","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Goyang-si Clinical Site 103","city":"Goyang-si","state":"Gyeonggi-do","country":"South Korea","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"Seongnam-si Clinical Site 104","city":"Seongnam-si","state":"Gyeonggi-do","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Cheongju-si Clinical Site 106","city":"Cheongju-si","state":"North Chungcheong","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Incheon Clinical Site 102","city":"Incheon","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Seoul Clinical Site 101","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul Clinical Site 107","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul Clinical Site 108","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul Clinical Site 109","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul Clinical Site 110","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Ulsan Clinical Site 105","city":"Ulsan","country":"South Korea","geoPoint":{"lat":35.53722,"lon":129.31667}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","url":"https://www.ono.co.jp/eng/rd/policy.html"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Of 104 subjects determined eligible, 1 had an unknown histological type and excluded.","groups":[{"id":"FG000","title":"Squamous Non-small Cell Lung Cancer (NSCLC)","description":"In each treatment cycle, patients received an intravenous infusion of nivolumab (ONO-4538) at a dose of 3 mg/kg with 2-week dosing intervals for 6 weeks. Radiological assessments (computed tomography/ magnetic resonance imaging) were conducted every 6 weeks. Patients entered subsequent treatment cycles unless they met discontinuation criteria, including disease progression, unacceptable adverse events, and consent withdrawal. Patients who were discontinued for any of these reasons entered the follow-up phase."},{"id":"FG001","title":"Non-squamous Non-small Cell Lung Cancer (NSCLC)","description":"In each treatment cycle, patients received an intravenous infusion of nivolumab (ONO-4538) at a dose of 3 mg/kg with 2-week dosing intervals for 6 weeks. Radiological assessments (computed tomography/ magnetic resonance imaging) were conducted every 6 weeks. Patients entered subsequent treatment cycles unless they met discontinuation criteria, including disease progression, unacceptable adverse events, and consent withdrawal. Patients who were discontinued for any of these reasons entered the follow-up phase."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"58"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"43"}]}],"dropWithdraws":[{"type":"Did not receive the investigational product","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Met an exclusion criteria","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Disease progression","reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"27"}]},{"type":"Other than above reasons","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."},{"id":"BG001","title":"Non-squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"100"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69.5","lowerLimit":"40","upperLimit":"80"},{"groupId":"BG001","value":"63.5","lowerLimit":"29","upperLimit":"77"},{"groupId":"BG002","value":"66.5","lowerLimit":"29","upperLimit":"80"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"<65 years","categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"44"}]}]},{"title":"65-<75 years","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"41"}]}]},{"title":">=75 years","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"15"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"22"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"78"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"South Korea","categories":[{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"100"}]}]}]},{"title":"Histology","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Squamous","measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"44"}]},{"title":"Adenocarcinoma","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"50"}]},{"title":"Large cell carcinoma","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Disease stage","description":"Clinical stage was diagnosed according to UICC-TNM classification (7th edition) . Generally, the prognosis becomes worse as the stage progresses.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"IIIB","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"}]},{"title":"IV","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"91"}]},{"title":"Recurrent","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Prior treatment for NSCLC: Surgery","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"}]},{"title":"No","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"82"}]}]}]},{"title":"Prior treatment for NSCLC: Radiotherapy","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"24"}]},{"title":"No","measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"76"}]}]}]},{"title":"Prior treatment for NSCLC-Medication: Platinum-based chemotherapy","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"100"}]},{"title":"No","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Prior treatment for NSCLC-Medication: EGFR-TKI therapy","description":"EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitors.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"8"}]},{"title":"No","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"92"}]}]}]},{"title":"Number of treatment regimens for NSCLC","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"1","measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"91"}]},{"title":"2","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"9"}]}]}]},{"title":"Smoking history","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Never smoker","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"22"}]},{"title":"Current/former smoker","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"78"}]}]}]},{"title":"Eastern Cooperative Oncology Group performance status","description":"PS 0 means \"fully active, able to carry on all pre-disease performance without restriction\" whereas PS 1 means \"restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work\". Generally, the prognosis worsens as PS worsens.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"0","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"14"}]},{"title":"1","measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"86"}]}]}]},{"title":"Brain metastasis","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"26"}]},{"title":"No","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"74"}]}]}]},{"title":"EGFR status","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Positive","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"8"}]},{"title":"Negative","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"56"}]},{"title":"Unknown","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"36"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Response Rate (Centrally Assessed)","description":"Response rate (%) = (Number of subjects whose confirmed best overall response was complete response (CR) or partial response (PR) / Total number of FAS)\\*100. 95% Confidence interval (CI) was calculated by Wilson method.","populationDescription":"Full analysis set（FAS): This set was defined as a full group of subjects who were included in safety analysis set, which was defined as group of subjects who were enrolled and received at least one dose of the study drug. This set was used in the primary efficacy evaluation.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase (up to approximately 10 months).Follow-up phase: 28 days after final dose or for discontinuation occurring 28 or fewer days after final dose.","groups":[{"id":"OG000","title":"Squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."},{"id":"OG001","title":"Non-squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","lowerLimit":"6.4","upperLimit":"26.7"},{"groupId":"OG001","value":"19.6","lowerLimit":"11.3","upperLimit":"31.8"}]}]}]},{"type":"SECONDARY","title":"Response Rate (Investigator-assessed)","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase (up to approximately 10 months).Follow-up phase: 28 days after final dose or for discontinuation occurring 28 or fewer days after final dose.","groups":[{"id":"OG000","title":"Squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."},{"id":"OG001","title":"Non-squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","lowerLimit":"9.5","upperLimit":"32.0"},{"groupId":"OG001","value":"19.6","lowerLimit":"11.3","upperLimit":"31.8"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival (days) = (the date of death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"Follow-up phase: Every 6 months after the first day of treatment of the last subject enrolled in the study, until death or study completion.","groups":[{"id":"OG000","title":"Squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."},{"id":"OG001","title":"Non-squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"249.0","upperLimit":"NA","comment":"During the period up to the cut-off, 27 (27.0%) out of 100 subjects in the FAS died (fatal) \\[squamous NSCLC 12 subjects (27.3%), non-squamous NSCLC 15 subjects (26.8%)\\] and median overall survival could not be estimated. And the upper limit of the 95% CI for the median could not be obtained. There was an insufficient number of participants with events."},{"groupId":"OG001","value":"NA","lowerLimit":"291.0","upperLimit":"NA","comment":"During the period up to the cut-off, 27 (27.0%) out of 100 subjects in the FAS died (fatal) \\[squamous NSCLC 12 subjects (27.3%), non-squamous NSCLC 15 subjects (26.8%)\\] and median overall survival could not be estimated. And the upper limit of the 95% CI for the median could not be obtained. There was an insufficient number with events."}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (Centrally Assessed)","description":"Progression free survival (days) = (the earlier date of the first documented progressive disease (PD) or death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or until central PD was confirmed or data cut-off point.Follow-up phase: Until beginning subsequent treatment for non-small cell lung cancer or PD or recurrence.","groups":[{"id":"OG000","title":"Squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."},{"id":"OG001","title":"Non-squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","lowerLimit":"41.0","upperLimit":"182.0"},{"groupId":"OG001","value":"162.0","lowerLimit":"43.0","upperLimit":"216.0"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (Centrally Assessed)","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Duration of response (days) = (the date of the first documented PD or death due to any cause after response was confirmed) - (the date of the first confirmed CR or PR) + 1. Median (95% CI) was calculated by Kaplan-Meier method.","populationDescription":"FAS","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase(up to approximately 10 months).Follow-up phase: Until beginning subsequent treatment for non-small cell lung cancer or PD or recurrence.","groups":[{"id":"OG000","title":"Squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."},{"id":"OG001","title":"Non-squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\"."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"56"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"145.0","upperLimit":"NA","comment":"Median duration of response could not be estimated and the upper limit of the 95% CI for the median could not be obtained. There was an insufficient number of participants with events."},{"groupId":"OG001","value":"NA","lowerLimit":"85.0","upperLimit":"NA","comment":"Median duration of response could not be estimated and the upper limit of the 95% CI for the median could not be obtained. There was an insufficient number of participants with events."}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From the start of the first dose of the investigational product to 28 days after the final dose or discontinuation, occurring 28 or fewer days after the final dose, or data cut-off point (June 2, 2015), whichever occurs first. Adverse events will be monitored and assessed before each dose and as needed based on clinical symptoms. Total assessment period: up to 10 months per participant.","description":"The analysis was performed on SAS, which was defined as group of subjects who received at least one dose of the study drug. Adverse Events (AEs) were analyzed based on treatment emergent AEs (TEAEs), defined as any event not present prior to initiation of study drug that first appeared following exposure to study drug or any event already presented that worsened relative to the pre-treatment state following the treatment. All-Cause Mortality was defined as incidence of TEAEs leading to death.","eventGroups":[{"id":"EG000","title":"Squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\".","deathsNumAffected":12,"deathsNumAtRisk":44,"seriousNumAffected":20,"seriousNumAtRisk":44,"otherNumAffected":24,"otherNumAtRisk":44},{"id":"EG001","title":"Non-squamous Non-small Cell Lung Cancer (NSCLC)","description":"Refer to \"Participant Flow\".","deathsNumAffected":15,"deathsNumAtRisk":56,"seriousNumAffected":17,"seriousNumAtRisk":56,"otherNumAffected":36,"otherNumAtRisk":56}],"seriousEvents":[{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":44},{"groupId":"EG001","numAffected":4,"numAtRisk":56}]},{"term":"Sialoadenitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Subdural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Metastases to spine","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Vocal cord paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Major depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":3,"numAtRisk":56}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":56}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":2,"numAtRisk":56}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]},{"term":"Infarction","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":56}]}],"otherEvents":[{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":44},{"groupId":"EG001","numAffected":11,"numAtRisk":56}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":44},{"groupId":"EG001","numAffected":2,"numAtRisk":56}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":44},{"groupId":"EG001","numAffected":5,"numAtRisk":56}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":44},{"groupId":"EG001","numAffected":6,"numAtRisk":56}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":44},{"groupId":"EG001","numAffected":4,"numAtRisk":56}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":3,"numAtRisk":56}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":44},{"groupId":"EG001","numAffected":5,"numAtRisk":56}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":44},{"groupId":"EG001","numAffected":4,"numAtRisk":56}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":44},{"groupId":"EG001","numAffected":11,"numAtRisk":56}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":44},{"groupId":"EG001","numAffected":3,"numAtRisk":56}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":44},{"groupId":"EG001","numAffected":3,"numAtRisk":56}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":44},{"groupId":"EG001","numAffected":8,"numAtRisk":56}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":3,"numAtRisk":56}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":3,"numAtRisk":56}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":3,"numAtRisk":56}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":44},{"groupId":"EG001","numAffected":20,"numAtRisk":56}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":6,"numAtRisk":56}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":4,"numAtRisk":56}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":44},{"groupId":"EG001","numAffected":3,"numAtRisk":56}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":44},{"groupId":"EG001","numAffected":5,"numAtRisk":56}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":44},{"groupId":"EG001","numAffected":6,"numAtRisk":56}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":44},{"groupId":"EG001","numAffected":6,"numAtRisk":56}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":3,"numAtRisk":56}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":44},{"groupId":"EG001","numAffected":5,"numAtRisk":56}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":4,"numAtRisk":56}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":44},{"groupId":"EG001","numAffected":15,"numAtRisk":56}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":44},{"groupId":"EG001","numAffected":15,"numAtRisk":56}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":44},{"groupId":"EG001","numAffected":9,"numAtRisk":56}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":44},{"groupId":"EG001","numAffected":4,"numAtRisk":56}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":44},{"groupId":"EG001","numAffected":12,"numAtRisk":56}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":44},{"groupId":"EG001","numAffected":5,"numAtRisk":56}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this tiral prior to submission for publication/presentation."},"pointOfContact":{"title":"Medical Information Center","organization":"Ono Pharmaceutical Co., Ltd.","email":"clinical_trial@ono-pharma.com"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-11-02","uploadDate":"2023-08-23T19:24","filename":"Prot_000.pdf","size":1404499},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-07-29","uploadDate":"2023-09-01T00:32","filename":"SAP_001.pdf","size":1039025}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"interventionBrowseModule":{"meshes":[{"id":"D000077594","term":"Nivolumab"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}